Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
RP

NASDAQ · RPRX

Royalty Pharma plc

Healthcare · Biotechnology

$67.18

Up+$1.25 (+1.90%)

Updated Oct 31, 2026, 6:47 PM

SID Score

7.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
16.85B
P/E ratio
16.44
Dividend yield
1.31%
52-week range
$36.03 – $66.29
Volume
4.66M
Avg. volume
4.22M

Price performance · RPRX

RPRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

RPRX closed at $67.18 after 21 trading sessions, up 17.53% for the selected period.

Last close
$67.18
Period change
+17.53%
Period low
$56.21
Period high
$67.18
Daily close
View OHLC price history
RPRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$67.00$67.705$66.40$67.184.66M
Oct 29, 2026$65.34$66.29$64.93$65.932.45M
Oct 28, 2026$64.815$65.335$63.485$64.822.41M
Oct 27, 2026$64.71$65.505$64.45$65.282.7M
Oct 26, 2026$64.14$65.35$64.055$64.764.11M
Oct 23, 2026$63.50$63.97$63.01$63.864.02M
Oct 22, 2026$62.34$63.84$62.34$63.752.81M
Oct 21, 2026$62.10$62.90$62.00$62.152.74M
Oct 20, 2026$60.92$62.42$60.78$62.252.49M
Oct 19, 2026$60.535$61.1232$60.04$60.272.81M
Oct 16, 2026$59.89$61.31$59.72$60.965.79M
Oct 15, 2026$59.75$60.41$59.50$59.623.41M
Oct 14, 2026$56.93$59.08$56.78$58.992.83M
Oct 13, 2026$57.70$57.97$56.42$56.573.58M
Oct 12, 2026$57.04$57.92$56.85$57.782.47M
Oct 9, 2026$56.03$57.08$55.72$56.932.88M
Oct 8, 2026$56.57$56.71$55.13$56.212.85M
Oct 7, 2026$56.605$57.155$56.405$56.763.67M
Oct 6, 2026$56.66$57.13$56.04$56.442.43M
Oct 5, 2026$57.10$57.25$56.005$56.663.96M
Oct 2, 2026$57.635$57.91$56.96$57.162.23M

Latest RPRX news

The latest Smart Investors Daily articles mentioning RPRX.

Stock researchCompany · Overview

RPRX research

Overview

Company profile and research snapshot.

Company profile

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$47.00
Implied upside
—
Analysts
—
RPRX recent ratings
DateFirmRatingTarget
Oct 7, 2026Morgan StanleyOverweight—
Sep 8, 2026TD CowenBuy—
Aug 7, 2026JP MorganOverweight—
Jul 13, 2026TD CowenBuy—
May 7, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Missed Royalty Pharma's Rally? Here's The Case Holders Backed

Royalty Pharma kept printing upbeat headlines, with recurring royalty receipts rising and new late stage deals like cliramitug and rusfertide added to the portfolio, even as one quarterly net margin compressed from 5.6% to 2.7%. For Royalty Pharma shareholders, the return over the past year was 74.7%, including dividends. If you had been weighing the bullish growth story against debt, pricing pressure, and pipeline risk in October 2025, what made that trade off worth accepting? The useful...

Yahoo · Oct 16, 2026

Royalty Pharma declares fourth quarter 2026 dividend

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on December 10, 2026, to shareholders of record at the close of business on November 13, 2026. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceu

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By